ReviewAnnals of medicine2026
The role of protein palmitoylation in disease pathogenesis and therapeutic innovation.
Review in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProtein palmitoylation is a significant post-translational modification that influences protein stability, localization, and signaling through the addition of palmitoyl groups to cysteine, serine/threonine, or lysine residues. It is facilitated by palmitoyltransferases (e.g. zDHHC family) and reversed by depalmitoylases such as APT1/2. Dysregulation of this modification has been associated with several diseases, including diabetes and cancer.
objectiveThis review aims to evaluate the role of palmitoylation in metabolic disorders and cancer, as well as to assess recent therapeutic strategies aimed at targeting this modification.
methodsA literature review was conducted focusing on the implications of S-palmitoylation, N-palmitoylation, and O-palmitoylation in various diseases, and the effectiveness of recent therapeutic approaches that target these pathways.
conclusionFindings highlight the critical role of palmitoylation in disease mechanisms and therapeutic potentials. While promising strategies have emerged, challenges remain in developing selective inhibitors for the zDHHC enzymes. Ongoing research is necessary to further elucidate the molecular mechanisms and advance drug development tailored to manage metabolic diseases and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.